Double blind randomized clinical trial comparing noradrenaline plus placebo versus noradrenaline plus terlipressin in septic shock.

Conditions

Septic Shock

Brief summary

Reduction of organ failure evaluated by SOFA scale, Increase in ICU-free days of life

Detailed description

Increase in lactate clearance., Increase of the days with life free of mechanical ventilation., Increase in vasopressor-free days of life, Mortality, Reduction of the need for continuous renal replacement therapy (CRRT)., Reduction of the total equivalent dose of vasopressors, No increase in adverse effects related to the administration of vasopressors, Association of mortality with genetic variants of the vasopressin 1a receptor and the LNPEP gene., Association between the achievement of the combined primary endpoint and the genetic variants of the vasopressin receptor 1a and the LNPEP gene., Association between the appearance of adverse effects due to the use of terlipressin, and the genetic variants of the Vasopressin 1a receptor and LNPEP gene.

Related papers

No related papers found yet.

Interventions

DRUGNOREPINEPHRINE

DRUGTerlipresina acetato EVER Pharma 1 mg solución inyectable

DRUGSolution in a vial with the same external appearance as terlipressin

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Reduction of organ failure evaluated by SOFA scale, Increase in ICU-free days of life	—

Secondary

Measure	Time frame
Increase in lactate clearance., Increase of the days with life free of mechanical ventilation., Increase in vasopressor-free days of life, Mortality, Reduction of the need for continuous renal replacement therapy (CRRT)., Reduction of the total equivalent dose of vasopressors, No increase in adverse effects related to the administration of vasopressors, Association of mortality with genetic variants of the vasopressin 1a receptor and the LNPEP gene., Association between the achievement of the combined primary endpoint and the genetic variants of the vasopressin receptor 1a and the LNPEP gene., Association between the appearance of adverse effects due to the use of terlipressin, and the genetic variants of the Vasopressin 1a receptor and LNPEP gene.	—

Measure

Time frame

Increase in lactate clearance., Increase of the days with life free of mechanical ventilation., Increase in vasopressor-free days of life, Mortality, Reduction of the need for continuous renal replacement therapy (CRRT)., Reduction of the total equivalent dose of vasopressors, No increase in adverse effects related to the administration of vasopressors, Association of mortality with genetic variants of the vasopressin 1a receptor and the LNPEP gene., Association between the achievement of the combined primary endpoint and the genetic variants of the vasopressin receptor 1a and the LNPEP gene., Association between the appearance of adverse effects due to the use of terlipressin, and the genetic variants of the Vasopressin 1a receptor and LNPEP gene.

—

Countries

Spain

Outcome results

None listed